Yahoo Web Search

Search results

1. www.investing.com › news › stock-market-newsEarnings call: AstraZeneca reports a revenue climbing to nearly...

   www.investing.com › news › stock-market-news

   • Cached

   1 day ago · Published 07/25/2024, 06:46 PM. 0. AZN. -. AstraZeneca (NASDAQ: AZN) has reported a significant increase in its financial performance for the first half of 2024, with total revenue climbing 18% to ...

2. Top stories

   • 

     AstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease Medicines

     On Thursday, AstraZeneca Plc (NASDAQ:AZN) reported second-quarter sales of $12.94 billion, up 13% year over year (+17% at constant currency), beating the consensus of $12.75 ...

     Benzinga via Yahoo

     14 hours ago

   • GuruFocus.com via Yahoo

     Eaton Vance Worldwide Health Sciences Fund's Strategic Moves in Q2 2024: Spotlight on ...

     8 hours ago

   • Benzinga via Yahoo

     Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants

     2 days ago

   • Benzinga via Yahoo

     Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand

     15 hours ago

   • 

     Reuters via Yahoo

     Analysis-Drug giants eye China for deals despite growing Sino-US tensions

     3 days ago

   • Investing.com via Yahoo

     Biden's speech, Ford's miss, European earnings - what's moving markets

     The tech-led selloff looks set to continue Thursday, while Ford has also disappointed with a second-quarter profit miss. President Joe Biden addressed the nation on Wednesday for the first time ...

     23 hours ago

   View all

3. www.sharecast.com › news › news-and-announcementsAstraZeneca hikes full-year guidance after strong first half

   www.sharecast.com › news › news-and-announcements

   • Cached

   1 day ago · AstraZeneca revised its full-year 2024 guidance upwards on Thursday, anticipating mid-teens percentage growth in both total revenue and core earnings per share at constant exchange rates.

4. www.investors.com › news › technologyAstraZeneca Hopes This Differentiated Tact Will Offer A 'Powerful...

   www.investors.com › news › technology

   7 hours ago · On today's stock market, however, AstraZeneca stock shed 1.5% to 78.52. Shares undercut their 50-day moving average, ... Realtime quote and/or trade prices are not sourced from all markets.

5. www.thestar.com.my › business › 2024/07/25AstraZeneca raises outlook on strong cancer drug sales

   www.thestar.com.my › business › 2024/07/25

   • Cached

   1 day ago · The shares were down 2.7% at 0730 GMT. The UK's most valuable company in terms of its market capitalisation of 189.4 billion pounds ($243.89 billion) has evolved significantly since CEO Pascal ...

6. news.sky.com › story › nices-methodology-means-people-withNICE's methodology means people with cancer aren't getting drugs...

   news.sky.com › story › nices-methodology-means-people-with

   • Cached

   1 day ago · He was speaking as AstraZeneca, the biggest company in the FTSE-100, was reporting a 7% rise in its core operating profit, to $8.4bn, for the first six months of the year and upgraded its sales ...

7. www.streetinsider.com › Corporate+News › AstraZeneca+(AZNAstraZeneca (AZN) reports FDA AdCom reviewed Imfinzi for...

   www.streetinsider.com › Corporate+News › AstraZeneca+(AZN

   • Cached

   7 hours ago · Tweet Share E-mail. Get Alerts AZN Hot Sheet . Price: $78.52 -1.49% Overall Analyst ... (ODAC) acknowledged that AstraZeneca (NASDAQ: AZN) Imfinzi (durvalumab) met the primary endpoint of ...

8. www.proactiveinvestors.com.au › companies › newsFTSE 100 live: Index plunges to three-month low, as AstraZeneca,...

   www.proactiveinvestors.com.au › companies › news

   • Cached

   1 day ago · The FTSE 100 is heading lower as investors seem to be unimpressed by results from some of the index's big guns, now down over 1% to 8,070. Shares in the Footsie's largest company, AstraZeneca PLC ...